Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma

Published on 13 Sep 2024
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Axicabtagene ciloleucel suspension for intravenous infusion for treating patients 18 years of age and above with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy, and who are intended for transplant.

Funding status

Axicabtagene ciloleucel suspension for intravenous infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 April 2025.

Axicabtagene ciloleucel should be used in line with the additional clinical criteria listed in the Annex.

Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma (Updated 17 Feb 2025) [PDF, 227 KB]

PES Chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell-lymphoma (updated 17 Feb 2025) [PDF, 106 KB]